Date published: 2026-1-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

KV9.1 Inhibitors

KV9.1 inhibitors represent a class of chemical compounds that selectively target the KV9.1 potassium channel, which is part of the larger family of voltage-gated potassium (KV) channels. The KV9.1 subunit belongs to the electrically silent KV subfamily, meaning that while it does not form functional potassium channels by itself, it can co-assemble with other subunits, such as those from the KV2 family, to modulate their function. These inhibitors work by blocking or reducing the activity of the heteromeric channels that are formed by the combination of KV9.1 with other subunits. The blockade of these channels can lead to alterations in potassium ion flux, which is critical in maintaining the resting membrane potential and in regulating action potential dynamics in excitable cells. The modulation of KV9.1-containing channels can influence cell membrane excitability, thereby affecting various physiological processes where potassium currents play a crucial role.

In terms of chemical diversity, KV9.1 inhibitors encompass a wide range of molecular structures, from small organic molecules to more complex ligands. The inhibitors often interact with the channel in a voltage-dependent manner, meaning their binding and efficacy can vary depending on the membrane potential of the cell. These compounds can bind to specific regions of the channel, including the pore domain or other regulatory sites that influence the gating mechanism. Structural studies of these inhibitors have shown that many of them can induce conformational changes in the channel, leading to either partial or complete inhibition of potassium ion flow. Research into KV9.1 inhibitors continues to explore their precise binding affinities, kinetic properties, and structural characteristics, with a focus on understanding how these interactions modulate the biophysical properties of KV9.1-containing channels.

SEE ALSO...

Items 11 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$66.00
$325.00
$587.00
$1018.00
28
(1)

By binding to retinoic acid receptors, Retinoic Acid could alter the transcriptional landscape, potentially leading to the repression of genes like KCNS1 that encode for KV9.1.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$31.00
$47.00
$84.00
$222.00
19
(3)

This compound could reduce the expression of the KCNS1 gene by increasing histone acetylation, which could suppress the recruitment of transcriptional activators to the KCNS1 gene locus.